Business Wire

SUSMED’s DTx Approved in Japan for the Treatment of Insomnia


SUSMED, Inc. (TOKYO:4263) announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare (the ”MHLW”) of SUSMED Med CBT-i® App for Insomnia (the ”product”). SUSMED is in the process of applying for insurance coverage, and market launch.

About Insomnia

Insomnia is a sleep disorder with difficulty falling asleep or staying asleep, early awakening and so on. It is also the most common complaints in primary care.

The prevalence of difficulty falling asleep is reported to be 8.3% of the Japanese population and, for insomnia as a whole, 21.4%1. Insomnia is considered to be a socially important issue affecting patients’ quality of life, as prolonged insomnia is a factor that increases the risk of developing psychiatric disorders such as depression and anxiety disorders.

Currently, in the treatment of insomnia in Japan, drug therapy with sleeping pills is widely used2. Although sleeping pills have the advantage of immediate effects, such as shortening the latency to fall asleep and improving difficulty staying asleep, they have kinds of side effects such as physical symptoms of lightheadedness or falling down, and carryover effects of headache or fatigue. They also cause drug dependence. Thus, it is required to use the minimum necessary amount of sleeping pills.

In addition to drug treatment, there are other treatment options like sleep hygiene instruction or cognitive behavioral therapy for insomnia (CBT-I). They are selected based on the patients’ symptoms, and in the United States, CBT-I is recommended as the first choice for insomnia treatment3. However, implementing CBT-I requires time-consuming instruction, and CBT-I is not widely used in Japan due to a lack of medical professionals.

New treatment option for insomnia with this app

As mentioned above, drug therapy with sleeping pills is the preferred treatment for insomnia in Japan. Considering this situation, academic societies and the MHLW have proposed reducing the number of pills and the duration of prescriptions, but the number of treatment options has not increased, and the underlying problem remained.

With this regulatory approval, the product can provide with CBT-I to be prescribed in the form of a smartphone application, and it becomes a treatment option for insomnia other than drug therapy. SUSMED entered into a marketing alliance agreement with Shionogi & Co. in December 2021 in order to widely promote the product to medical institutions4. It is expected to improve the current situation where CBT-I is not widely used due to the shortage of medical professionals, and to enable treatment of insomnia while reducing reliance on drug therapy. In the U.K., where evidence for the treatment of insomnia with smartphone applications has been accumulated, the National Institute for Health and Clinical Excellence (NICE) has recommended the use of CBT-I based applications for insomnia treatment in its 2022 guidelines5.

About the product

The product is a smartphone application used to provide CBT-I with insomnia patients. It has therapeutic effects on insomnia symptoms by following instructions prompted by the product over a 9-week period. In addition, the progress of insomnia treatment can be shared to physicians through the management system, that supports the treatment process.


Official Name


SUSMED Med CBT-i App® for Insomnia

General Name


Program for Insomnia

Approval Number





It is a prescription-only digital therapeutic intended to assist physicians providing CBT-I with patients in the treatment of insomnia

Date of Approval


February 15, 2023

Marketing Authorization Holder



Clinical trial results for the product

Effect of Smartphone-based Cognitive Behavioral Therapy App on Insomnia: a Randomized, Double-blind Study
SLEEP, zsac270,


Kim K, Uchiyama M, Okawa M, Liu X, Ogihara R. An epidemiological study of insomnia among the Japanese general population. Sleep. 2000 Feb 1;23(1):41-7


MHLW Research Group and Japan Sleep Society Working Group “Clinical Practice Guideline for Appropriate Use and Withdrawal of Sleep Medications” (in Japanese)


Institutes of Health. State of the science conference statement on manifestations and management of chronic insomnia in adults, June 13-15, 2005. Sleep. 2005;28(9):1049-1057.


Press release, “Commercialization agreement with SHIONOGI for DTx for Insomnia”,


To view this piece of content from, please give your consent at the top of this page.

Contact information


About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

STEMCELL Technologies Partners with Science World to Empower Girls Pursuing Science-related Careers25.9.2023 21:02:00 EEST | Press release

STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce it will be the presenting partner of the Girls and STEAM Summit at Science World in Vancouver. This press release features multimedia. View the full release here: STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce it will be the presenting partner of the Girls and STEAM Summit at Science World in Vancouver, British Columbia. The Summit, which takes place on November 4, 2023, is a full-day event with workshops, hands-on activities, a keynote presentation, and sessions with experienced mentors who work in STEAM (science, technology, engineering, art and design, and math). “Science is about so much more than what happens in the laboratory. It provides a lens that can instill a deep-seated curiosity in young minds and enrich every aspect of our lives,” said Sharon Louis, Senior Vice President of Research and Devel

AngloGold Ashanti plc Completes the Primary Listing of Its Ordinary Shares on the NYSE and Commences Trading25.9.2023 17:11:00 EEST | Press release

AngloGold Ashanti is pleased to announce that it has today completed its corporate restructuring, with a primary listing of its shares on the New York Stock Exchange (NYSE) and a corporate domicile in the UK. The corporate restructuring was first announced on 12 May of this year and approved by the shareholders of AngloGold Ashanti Limited on 18 August. “The move of our primary listing to the NYSE provides us with improved access to the world’s largest capital market and places us alongside the industry’s highest-valued gold companies,” said AngloGold Ashanti CEO Alberto Calderon. “This signifies an important new era for AngloGold Ashanti strengthening our corporate infrastructure as we continue to focus on taking performance from our world class asset base to the next level.” The ordinary shares of AngloGold Ashanti plc commenced trading on the NYSE today, 25 September 2023, maintaining the ticker symbol AU. Trading in the AngloGold Ashanti Limited American Depositary Shares (ADSs) on

PLIDCO Launches New Line of Hydrogen-Compatible Fittings25.9.2023 17:00:00 EEST | Press release

The Pipe Line Development Company (PLIDCO), the leader in pipeline leak repair and maintenance fittings, announced today a new range of products for use with hydrogen pipelines in response to the emerging transition toward hydrogen and other alternative energy sources. This press release features multimedia. View the full release here: PLIDCO Hydrogen-Compliant Fittings Brochure (Photo: Business Wire) Designed for onshore and subsea high-pressure emergency pipeline repairs and routine pipeline maintenance applications, PLIDCO’s products are ideal for hydrogen, oil, gas, water, chemical, steam, slurry and other piping systems. Its high-pressure fittings are designed and manufactured to meet the highest quality standards, following ASME/ANSI codes and adhering to a strict quality control program. “As the shift toward a hydrogen-based energy system gains traction, we anticipate an emerging need for pipeline maintenance and repair p

MESTEC Wins Oracle® Global Leaders ISV of the Year Award25.9.2023 16:30:00 EEST | Press release

MESTEC is excited to accept the Oracle Global Leaders ISV of the Year Award at this year’s Oracle CloudWorld Conference. At over 50% annual growth, MESTEC is leading the manufacturing software category and welcoming some of the world’s most innovative and valuable manufacturers to its pioneering SaaS MES platform. MESTEC’s primary focus on helping manufacturers gain performance across 80+ key manufacturing KPIs, along with its rapid deployment time, is fuelling customer migration to the platform. MESTEC is part of the Eyelit Group, an emerging leader in manufacturing software platforms. Together with Eyelit advanced manufacturing software, the two platforms are seeing especially strong demand in semiconductor, automotive, medtech, aerospace and defence, battery, and solar industries. The platforms support all key manufacturing workflows including asset management, factory and equipment integration, automation, manufacturing execution (MES), recipe management, quality management, planni

ASMPT AMICRA and Teramount Collaborate to Advance Silicon Photonics Packaging25.9.2023 16:00:00 EEST | Press release

ASMPT AMICRA, a worldwide leading supplier of ultra-high precision die attach equipment that specializes in ultra-high precision die attach solutions, and Teramount Ltd, the leader in scalable fiber connectivity to chips, today announced a collaboration to address the challenge of connecting fibers to silicon photonic chips, to meet the ever-growing bandwidth demands in datacom and telecom applications. This press release features multimedia. View the full release here: A close collaboration between Teramount and ASMPT AMICRA on fiber connectivity to silicon photonics chips (Photo: Business Wire) In the rapidly evolving fields of artificial intelligence and high-performance networking, one of the primary challenges has been to achieve seamless fiber-to-chip connectivity. The collaboration between the two companies, based on placement of Teramount’s pioneering wafer-level self-aligning optical elements on customer’s Silicon Photo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom